Institute of Cancer Research UK has described lysyl oxidase homolog 2 (LOXL2) inhibitors reported to be useful for the treatment of cancer and fibrosis.
Bioversys AG has divulged compounds with the ability to interact with accessory gene regulator A (AgrA) and inhibit the expression of AgrA-regulated virulence factors.
Dana-Farber Cancer Institute Inc. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase ligand binding moiety covalently linked to an histone deacetylase 6 (HDAC6)/8 (HDAC8)-targeting moiety through a linker.
Sanofi SA has synthesized cyclic peptides acting as IL-23 receptor (IL-23R) antagonists reported to be useful for the treatment of psoriasis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and hidradenitis suppurativa.
Zentaur Therapeutics USA Inc. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Trioar Inc. has synthesized antibody-drug conjugates comprising antibodies targeting HER2 (Neu, erbB2) covalently linked to cytotoxic drugs (particularly, MMAE and MMAF) through a linker reported to be useful for the treatment of cancer.
Doma Biopharmaceutical (Suzhou) Co. Ltd. has disclosed antibody-drug conjugates comprising bispecific antibodies (E-6C4-M-2F11) targeting EGFR (HER1; erbB1) and hepatocyte growth factor receptors (HGFR; MET) covalently linked to cytotoxic drugs through a linker reported to be useful for the treatment of cancer.
China Pharmaceutical University has synthesized kaurane tetracyclic diterpenoid derivatives acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of arthritis and skin disorders.
Kissei Pharmaceutical Co. Ltd. has described 3,4-dihydroquinolin-2(1H)-one compounds acting as thyroid-stimulating hormone (thyrotropin) receptor (TSHR) antagonists reported to be useful for the treatment of hyperthyroidism, Graves’ disease and thyroid-associated ophthalmopathy.
RSS